# Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

> **NCT05432635** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 15 (estimated)

## Conditions studied

- B-Cell Non-Hodgkin Lymphoma
- Diffuse Large B-Cell Lymphoma
- Mantle Cell Lymphoma
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Transformed Non-Hodgkin Lymphoma
- Transformed Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Anti-CD19-CAR CMV-specific T-lymphocytes
- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **BIOLOGICAL:** Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- **PROCEDURE:** Myeloablative Conditioning

## Key facts

- **NCT ID:** NCT05432635
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2028-03-07
- **Final completion:** 2028-12-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05432635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05432635, "Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05432635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*